Logo

BCAX

Bicara Therapeutics Inc. Common Stock

BCAX

Bicara Therapeutics Inc. Common Stock • NASDAQ
$18.56 ▼ -2.32% (-0.44)
Market Cap $1.02 B
52w High $22.68
52w Low $7.80
Dividend Yield 0%
P/E 3.45
Volume 178.55K
Outstanding Shares 54.78M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $40.676M ▲ $-36.33M ▼ 0% $-0.67 ▼ $-36.234M ▼
Q2-2025 $0 $32.018M ▼ $-27.388M ▲ 0% $-0.5 ▲ $-31.999M ▲
Q1-2025 $0 $41.788M ▲ $-36.846M ▼ 0% $-0.68 ▼ $-41.769M ▼
Q4-2024 $0 $26.637M ▲ $-20.957M ▼ 0% $-0.38 ▼ $-26.622M ▼
Q3-2024 $0 $20.628M $-17.481M 0% $-0.32 $-20.613M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $290.167M ▼ $424.688M ▼ $21.908M ▲ $402.78M ▼
Q2-2025 $436.606M ▼ $453.587M ▼ $18.391M ▼ $435.196M ▼
Q1-2025 $462.065M ▼ $478.077M ▼ $19.12M ▼ $458.957M ▼
Q4-2024 $489.711M ▼ $569.195M ▲ $77.32M ▲ $491.875M ▼
Q3-2024 $520.758M $524.173M $14.618M $509.555M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-36.33M ▼ $-29.248M ▼ $-236.121M ▼ $436K ▲ $-264.933M ▼ $-29.29M ▼
Q2-2025 $-27.388M ▲ $-25.594M ▲ $0 $135K ▼ $-25.459M ▲ $-25.594M ▲
Q1-2025 $-36.846M ▼ $-28.106M ▲ $0 ▲ $460K ▲ $-27.646M ▲ $-28.106M ▲
Q4-2024 $-20.957M ▼ $-30.032M ▼ $-40K ▼ $-975K ▼ $-31.047M ▼ $-30.072M ▼
Q3-2024 $-17.481M $-17.224M $-8K $334.135M $316.903M $-17.232M

Five-Year Company Overview

Income Statement

Income Statement Bicara is still a pure research-stage biotech, so it has no product revenue yet. Its income statement is driven almost entirely by research and development and corporate overhead. Losses have been steady to slightly widening over the last few years as the pipeline advances, with per‑share losses increasing as the company invests more heavily in clinical trials. This pattern is typical for an early oncology company: money is going out to fund studies, while any potential revenue is still years away and dependent on clinical and regulatory success.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash, with essentially no debt, which lowers financial risk compared with a highly leveraged biotech. Total assets and shareholders’ equity have improved meaningfully in the most recent year, reflecting fresh capital from the SPAC/IPO process and prior financings. The shift from negative to positive equity is a notable de‑risking step, although the company still depends on external capital over time unless it secures partnerships or reaches commercial stage. Tangible assets beyond cash remain limited, as expected for a lean, R&D‑focused platform company.

Cash Flow

Cash Flow Cash flow is negative and driven by operating expenses, mainly research, clinical development, and overhead. Capital spending needs are minimal, so almost all cash burn reflects ongoing operations rather than heavy investment in physical infrastructure. This makes the burn rate relatively flexible but still significant given the cost of oncology trials. Management states that the current cash position should fund operations for several years, but that assumes trial timelines and costs stay roughly on plan and that no major setbacks force a strategic rethink.

Competitive Edge

Competitive Edge Competitively, Bicara is positioned around a differentiated scientific angle rather than scale. Its bifunctional antibody approach aims to hit tumor growth pathways and the tumor microenvironment at the same time, which is a more integrated strategy than many single‑target drugs. The lead asset has first‑in‑class status in its specific target combination and has secured an FDA Breakthrough Therapy Designation in head and neck cancer, which is an important credibility and speed advantage. However, it operates in a crowded, well‑funded oncology field with many large pharmaceutical competitors, and its fate is highly tied to the success of one lead program, which concentrates risk.

Innovation and R&D

Innovation and R&D Innovation is Bicara’s main asset. The company is building a platform around bifunctional and bispecific antibodies, with a flagship drug that combines EGFR blocking with TGF‑β trapping, and a follow‑on preclinical asset that delivers a potent immune‑stimulating cytokine directly to tumors. Early clinical data and regulatory recognition for the lead therapy suggest the science is promising. The pipeline beyond the lead candidate is still at an early stage, so the broader platform value is largely theoretical for now, but it does provide a path to expand into multiple tumor types and new targets if the approach continues to work.

Summary

Bicara is a very early‑stage, high‑risk, high‑uncertainty oncology company with no revenue, ongoing losses, and a business model fully dependent on future clinical and regulatory outcomes. Its financial profile is typical for a development‑stage biotech: cash‑heavy, debt‑light, with negative cash flow from operations and limited hard assets. The main strengths are a clearly differentiated scientific platform, a lead asset with encouraging early data and Breakthrough Therapy Designation, and a multiyear cash runway that reduces near‑term financing pressure. The main vulnerabilities are heavy reliance on one core drug, exposure to clinical trial and regulatory setbacks, intense competition in cancer therapeutics, and the long timeline before any potential commercial returns. Overall, the story hinges on whether the dual‑action antibody approach can translate from early promise into durable, late‑stage clinical success.

NEWS

November 10, 2025 · 7:30 AM UTC

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

October 13, 2025 · 7:30 AM UTC

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Read more